Alexandra Guillén
Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma
Guillén, Alexandra; Stiborova, Katerina; Ressel, Lorenzo; Blackwood, Laura; Finotello, Riccardo; Amores-Fuster, Isabel; Jama, Nimo; Killick, David
Authors
Katerina Stiborova
Lorenzo Ressel
Laura Blackwood
Riccardo Finotello
Isabel Amores-Fuster
Nimo Jama
David Killick
Contributors
Alexandra Guillen
Project Member
Abstract
Canine oral malignant melanoma (COMM) is considered a chemo-resistant cancer with a poor long-term prognosis. The melanoma-associated antigen A (MAGE-A) genes, which belong to the cancer-testis antigen family, are expressed in several different canine cancers but not in normal somatic tissue. This study evaluates the expression of MAGE-A proteins and their prognostic role in COMM. The study was conducted in 2 parts. During the first part, biopsies from oral malignant melanomas from 43 dogs were examined and immunohistochemically assessed for expression of MAGE-A proteins. For the second part, the association between MAGE-A expression and outcome was assessed using follow-up data which was available for 20 dogs whose primary tumour had been controlled with surgery +/ radiation therapy. MAGE-A proteins were expressed in 88.4% (38/43) of oral malignant melanomas and had a predominantly cytoplasmic expression pattern. Immunopositivity was observed in more than 50% of the cells in 21 dogs (48.8%). Immunostaining intensity was classified as weak, moderate and intense in 16 (37%), 16 (37%) and 6 (14%) cases, respectively. No staining for MAGE-A was seen in 5 dogs (11%). Dogs whose COMM had weak MAGE-A staining intensity had a median survival time (MST) of 320 days while this was 129 days for dogs with moderate and intense immunostaining (p = 0.161). Dogs whose COMM had >50% of positive staining neoplastic cells had an MST of 141 days and dogs with a staining <50% had an MST of 320 days (p = 0.164). MAGE-A expression did not influence survival in our cohort.
Citation
Guillén, A., Stiborova, K., Ressel, L., Blackwood, L., Finotello, R., Amores-Fuster, I., Jama, N., & Killick, D. (2021). Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma. Research in Veterinary Science, 137, 226-234. https://doi.org/10.1016/j.rvsc.2021.05.009
Journal Article Type | Article |
---|---|
Acceptance Date | May 12, 2021 |
Online Publication Date | May 15, 2021 |
Publication Date | 2021-07 |
Deposit Date | May 15, 2024 |
Journal | Research in Veterinary Science |
Print ISSN | 0034-5288 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 137 |
Pages | 226-234 |
DOI | https://doi.org/10.1016/j.rvsc.2021.05.009 |
Keywords | General Veterinary |
Additional Information | This article is maintained by: Elsevier; Article Title: Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma; Journal Title: Research in Veterinary Science; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rvsc.2021.05.009; Content Type: article; Copyright: Crown Copyright © 2021 Published by Elsevier Ltd. All rights reserved. |
You might also like
Mastocytosis in the skin in dogs: A multicentric case series
(2024)
Journal Article
Prognostic factors and outcome in cats with thymic epithelial tumours: 64 cases (1999‐2021)
(2023)
Journal Article
Molecular pathology in the cancer clinic – where are we now and where are we headed?
(2021)
Journal Article
Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia
(2024)
Journal Article
Downloadable Citations
About RVC Repository
Administrator e-mail: publicationsrepos@rvc.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search